Aristeia Capital L.L.C. Has $981,000 Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Aristeia Capital L.L.C. reduced its stake in Amphastar Pharmaceuticals by 21.7%, selling 9,400 shares during the first quarter, leaving it with 33,835 shares valued at approximately $981,000.
• Amphastar Pharmaceuticals’ stock opened at $29.42 and has seen a 12-month range between $20.39 and $53.96, with a current market capitalization of $1.37 billion.
• Recent analyst ratings for Amphastar Pharmaceuticals include a target price increase to $32.00 from Bank of America, while Piper Sandler lowered its target price to $25.00, reflecting mixed sentiment among analysts.

Aristeia Capital L.L.C. reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 21.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,835 shares of the company's stock after selling 9,400 shares during the period. Aristeia Capital L.L.C. owned 0.07% of Amphastar Pharmaceuticals worth $981,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in AMPH. Signaturefd LLC raised its stake in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after buying an additional 520 shares during the period. IFP Advisors Inc acquired a new stake in Amphastar Pharmaceuticals during the 1st quarter worth $34,000. GF Fund Management CO. LTD. acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth $38,000. GAMMA Investing LLC raised its stake in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Amphastar Pharmaceuticals during the 1st quarter worth $39,000. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:AMPH traded down $0.62 during midday trading on Friday, reaching $28.06. The company had a trading volume of 273,426 shares, compared to its average volume of 562,470. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. The business's 50 day moving average price is $25.66 and its 200 day moving average price is $25.67. The stock has a market cap of $1.30 billion, a PE ratio of 10.51 and a beta of 0.80. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $53.96.

Analyst Ratings Changes

AMPH has been the topic of several research analyst reports. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th. Finally, Bank of America lifted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $31.60.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.